Patent application number | Description | Published |
20130180588 | HIGH TO ULTRAHIGH MOLECULAR WEIGHT POLYETHYLENE BACKSHEETS FOR PHOTOVOLTAIC DEVICES AND METHODS RELATING THERETO - Generally, solar cell backsheets may include high to ultrahigh molecular weight polyethylene. Advantageously, said backsheets may be single layer structures. Said backsheets may be used in conjunction with photovoltaic devices, photovoltaic modules, photovoltaic arrays, or components thereof. Said backsheets may be formed by methods including compression molding, compression molding then skiving, RAM extrusion, screw extrusion, band sintering, and hybrids thereof. | 07-18-2013 |
20130312605 | GAS PHASE AIR FILTRATION - An adsorbent medium for removing gaseous contaminants from air comprises a porous self-supporting filter element produced by sintering particles of polyethylene having a molecular weight greater than 400,000 g/mol as determined by ASTM-D 4020 and an adsorbent. In one embodiment, the filter element comprises a body perforated by a plurality of holes extending in the direction of fluid flow in use and having a diameter of less than 10 mm. In another embodiment, the filter element comprises a panel wherein at least the surface of the panel presented, in use, to the incoming air comprises a plurality of projections. In a further embodiment, the filter element comprises a fibrous web having particles of the adsorbent secured to the web by the sintered polyethylene. | 11-28-2013 |
20130313196 | PROCESSES AND FILTERS FOR DESALINATION OF WATER - In a process for the desalination of water, an impure, salt-containing water feed is passed through one or more filter media to remove from the feed impurities having a particle size greater than 50 μm and produce a first filtered water stream. The first filtered water stream is then passed through at least one further filter having an average pore size of 1 μm to 60 μm produced from sintered polyethylene particles having a molecular weight of at least 4×10 | 11-28-2013 |
20140054217 | WASTEWATER AERATION - A process for the aeration of wastewater employs an aerator comprising a porous body having an average pore size from 5 to 250 μm produced by sintering a composition comprising polyethylene particles having a molecular weight of at least 3×10 | 02-27-2014 |
20150175787 | Tribologically Modified Ultrahigh Molecular Weight Polyethylene - A tribologically modified ultrahigh molecular weight polyethylene (UHMW-PE) polymer composition is disclosed. The UHMW-PE polymer composition is comprised of an UHMW-PE polymer and at least one tribological modifier. The tribological modifier may be comprised of a silicone powder, a silicone oil, an olefin oligomer, an ultrahigh molecular weight silicone, or any combination thereof. The composition and polymer article produced therefrom may exhibit improved tribological properties, such as a reduced coefficient of friction and low wear, when contacted against a counter-material in comparison to an unmodified UHMW-PE polymer composition. | 06-25-2015 |
Patent application number | Description | Published |
20100266600 | METHODS OF USING IL-31 ANTAGONISTS IN DISEASES MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE T CELLS - The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population. | 10-21-2010 |
20110212093 | METHODS OF TREATING DISEASES WHICH ARE MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE CELLS - The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population. | 09-01-2011 |
20110293514 | METHODS OF USING IL-31 MONOCLONAL ANTIBODIES TO REDUCE INFLAMMATION - The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies. | 12-01-2011 |
20120107310 | METHODS OF ANTAGONIZING SIGNAL TRANSDUCTION IN SPINAL CORD CELLS - Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 05-03-2012 |
20120207757 | METHODS OF ANTAGONIZING SIGNAL TRANSDUCTION IN SPINAL CORD CELLS - Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 08-16-2012 |
20120219540 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES - The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided. | 08-30-2012 |
20130177562 | METHODS OF ANTAGONIZING SIGNAL TRANSDUCTION IN DORSAL ROOT GANGLION CELLS - Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 07-11-2013 |
20130195855 | METHODS OF ANTAGONIZING SIGNAL TRANSDUCTION IN DORSAL ROOT GANGLION CELLS - Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 08-01-2013 |
20130203070 | METHODS OF USING IL-31 ANTAGONISTS IN DISEASES MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE T CELLS - The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population. | 08-08-2013 |
20140080181 | POLYNUCLEOTIDES ENCODING IL-31 MONOCLONAL ANTIBODIES - The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies. | 03-20-2014 |
20140127206 | METHODS OF TREATING PAIN USING AN IL-31 MONOCLONAL ANTIBODY - Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 05-08-2014 |
20140186346 | METHODS OF TREATING PAIN USING AN IL-31RA OR OSMR-B ANTAGONIST - Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 07-03-2014 |
20150132299 | METHODS OF TREATING NEURONAL INFLAMMATION USING AN IL-31 MONOCLONAL ANTIBODY - Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 05-14-2015 |
20150132300 | METHODS OF ANTAGONIZING SIGNAL TRANSDUCTION IN SPINAL CORD CELLS USING AN IL-31RA OR OSMR-B ANTAGONIST - Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 05-14-2015 |
20150368336 | IL-31 MONOCLONAL ANTIBODIES - The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies. | 12-24-2015 |
20160060335 | MITIGATION AND REVERSAL OF FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION AND RELATED SIGNALING PATHWAYS - The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function. | 03-03-2016 |
20160096885 | DISTINCT EFFECTS OF IFN-GAMMA AND IL-17 ON TL1A MODULATED INFLAMMATION AND FIBROSIS - Described herein are methods and compositions related to Inflammatory Bowel Disease. Specifically TL1A drives regional intestinal inflammation and fibrosis and is differentially modulated by IFN gamma and IL-17a. In one embodiment, the present invention is a method of diagnosing a condition in a subject by determining the presence or absence of IFN gamma and/or IL-17 and diagnosing the subject. | 04-07-2016 |
Patent application number | Description | Published |
20100159516 | ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution under alkaline conditions in the presence of one or more alkylamine and optionally one or more additional nucleophile to fragment and extract lignin. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation. | 06-24-2010 |
20100159517 | ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution, under alkaline conditions, in the presence of one or more organo-mercaptan and optionally one or more additional nucleophile to fragment and extract lignin. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation. | 06-24-2010 |
20100159518 | ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution under alkaline conditions in the presence of one of more sulfide (hydrosulfide) salt and optionally one or more additional nucleophile to fragment and extract lignin. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation. | 06-24-2010 |
20100159519 | ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution under alkaline conditions in the presence of elemental sulfur and optionally one or more alkylamine and/or one or more additional nucleophile to fragment and extract lignin. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation. | 06-24-2010 |
20100159520 | ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution under alkaline conditions in the presence of ammonia and optionally an additional nucleophile to fragment and extract lignin without loss of hemicellulose. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation. | 06-24-2010 |
20120187228 | ANHYDROUS AMMONIA TREATMENT FOR IMPROVED MILLING OF BIOMASS - Mechanical milling of biomass as a pretreatment to render the biomass readily saccharifiable requires high energy input. Preceding mechanical milling by treatment with anhydrous ammonia was found to greatly reduce the energy requirement for fine milling, providing a more economical pretreatment process for commercial use. | 07-26-2012 |
20120264173 | ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution under alkaline conditions in the presence of one or more alkylamine and optionally one or more additional nucleophile to fragment and extract lignin. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation. | 10-18-2012 |
20120270269 | ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution under alkaline conditions in the presence of ammonia and optionally an additional nucleophile to fragment and extract lignin without loss of hemicellulose. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation. | 10-25-2012 |
20140234926 | RECOMBINANT ANAEROBIC ACETOGENIC BACTERIA FOR PRODUCTION OF ISOPRENE AND/OR INDUSTRIAL BIO-PRODUCTS USING SYNTHESIS GAS - This invention provides for recombinant anaerobic acetogenic bacterial cells having one or more nucleic acids whereby isoprene, mevalonate and/or other industrial bio-products are produced in a substantially oxygen-free culture condition using synthesis gas as energy and/or carbon source. | 08-21-2014 |
Patent application number | Description | Published |
20140136218 | SYSTEMS AND METHODS FOR SUPPLY CHAIN MANAGEMENT - Systems and methods are directed to supply chain management. In particular, the tracking, tracing, authenticating, and reporting of supply chain events for products, is disclosed. Various embodiments can store, analyze, and track supply chain events and help to coordinate and maintain trading partner connections. Various embodiments also help to enhance patient safety, secure the supply chains for pharmaceuticals, medical devices, and other healthcare products, and help users to follow regulatory requirements. | 05-15-2014 |
20140136273 | SYSTEMS AND METHODS FOR SUPPLY CHAIN MANAGEMENT - Systems and methods are directed to supply chain management. In particular, the tracking, tracing, authenticating, and reporting of supply chain events for products, is disclosed. Various embodiments can store, analyze, and track supply chain events and help to coordinate and maintain trading partner connections. Various embodiments also help to enhance patient safety, secure the supply chains for pharmaceuticals, medical devices, and other healthcare products, and help users to follow regulatory requirements. | 05-15-2014 |
20140136291 | SYSTEMS AND METHODS FOR SUPPLY CHAIN MANAGEMENT - Systems and methods are directed to supply chain management. In particular, the tracking, tracing, authenticating, and reporting of supply chain events for products, is disclosed. Various embodiments can store, analyze, and track supply chain events and help to coordinate and maintain trading partner connections. Various embodiments also help to enhance patient safety, secure the supply chains for pharmaceuticals, medical devices, and other healthcare products, and help users to follow regulatory requirements. | 05-15-2014 |
Patent application number | Description | Published |
20100173340 | USE OF HEMATOPOIETIC GROWTH FACTOR INDUCIBLE NEUROKININ-1 (HGFIN) AS A NOVEL BIOMARKER - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for hematopoietic growth factor inducible neurokinin-1 (HGFIN), wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of renal injury or renal disease, and/or the rate of loss of renal function. In other embodiments, the invention provides a method of detecting an indicator of systemic inflammation. This method entails assaying a biological sample for HGFIN, wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of systemic inflammation. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | 07-08-2010 |
20110177613 | Use of periostin as a novel biomarker - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | 07-21-2011 |
20120329886 | USE OF PERIOSTIN AS A NOVEL BIOMARKER - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | 12-27-2012 |
20130344511 | USE OF HEMATOPOIETIC GROWTH FACTOR INDUCIBLE NEUROKININ-1 (HGFIN) AS A NOVEL BIOMARKER - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for hematopoietic growth factor inducible neurokinin-1 (HGFIN), wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of renal injury or renal disease, and/or the rate of loss of renal function. In other embodiments, the invention provides a method of detecting an indicator of systemic inflammation. This method entails assaying a biological sample for HGFIN, wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of systemic inflammation. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | 12-26-2013 |
20140135227 | USE OF PERIOSTIN AS A NOVEL BIOMARKER - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | 05-15-2014 |
Patent application number | Description | Published |
20080274499 | Polypeptides having alpha-glucosidase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having alpha-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 11-06-2008 |
20100120654 | Polypeptides having lipase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 05-13-2010 |
20100190680 | Polypeptides having lipase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 07-29-2010 |
20100192260 | Polypeptides having alpha-glucosidase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having alpha-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 07-29-2010 |
20110053822 | Polypeptides having lipase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 03-03-2011 |
20110171347 | Polypeptides having Alpha-glucosidase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having alpha-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 07-14-2011 |
20110224123 | POLYPEPTIDES HAVING LIPASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 09-15-2011 |
20110239333 | Polypeptides Having Xylanase Activity And Polynucleotides Thereof - The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 09-29-2011 |
20120058930 | POLYPEPTIDES HAVING LIPASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 03-08-2012 |
20120192316 | POLYPEPTIDES HAVING LIPASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 07-26-2012 |
20130014293 | Xylanase Variants and Polynucleotides Encoding Same - The present invention relates to variants of a parent xylanase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 01-10-2013 |
20130025005 | Polypeptides Having Lipase Activity And Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 01-24-2013 |
20130123163 | Polypeptides Having Lipase Activity And Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 05-16-2013 |
20130152234 | Polypeptides Having Lipase Activity And Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 06-13-2013 |
20150082493 | GH61 Polypeptide Variants and Polynucleotides Encoding Same - The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 03-19-2015 |
20150197737 | Polypeptides Having Xylanase Activity And Polynucleotides Thereof - The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 07-16-2015 |
Patent application number | Description | Published |
20140102107 | HOUSING STRUCTURE WITH IMPROVED SEAL AND COOLING - A housing structure for a turbo-engine, especially for a gas turbine or an aircraft engine, includes an outer housing wall and an inner housing wall, the inner and outer housing walls annularly enclosing a flow channel for the turbo-engine and being spaced apart radially from the flow channel. At least one heat shield is arranged between the inner and outer housing walls, and a bar or a fixture projects at least somewhat radially from the inner housing wall. The bar or the fixture has on at least one side a broadening element that includes a sealing face against which the heat shield is positioned in a sealing manner. | 04-17-2014 |
20140105731 | AXIAL SEAL IN A CASING STRUCTURE FOR A FLUID FLOW MACHINE - A casing structure for a fluid flow machine, in particular for a gas turbine or an aircraft engine, including an outer casing wall and an inner casing wall, which annularly surround a flow channel of the fluid flow machine and are spaced apart in a radial direction with respect to the flow channel. At least one cavity is formed between the inner and outer casing walls. The cavity is axially divided into at least two regions which are separated from each other by an axial seal in such a way that different pressure conditions are created according to the axial position of these regions, which different pressure conditions correspond to the pressure conditions in the flow channel. A corresponding fluid flow machine such as, for example, an aircraft engine. | 04-17-2014 |
20140112768 | FORM-FITTING HOUSING COMPONENT COMBINATION AND METHOD FOR THE MANUFACTURE THEREOF - A component combination for a shell of a flow channel ( | 04-24-2014 |
20140119902 | SEAL CARRIER ATTACHMENT FOR A TURBOMACHINE - A housing structure for a turbomachine having a stationary blade ring annularly surrounding a flow channel, and having a seal carrier ring which also annularly surrounds the flow channel, the stationary blade ring and the seal carrier ring being connected to each other, and either the stationary blade ring or the seal carrier ring having a one-sidedly open receptacle in the radial direction in relation to the flow channel and a radially projecting engagement area which corresponds to the connected seal carrier ring or stationary blade ring and which is held in a form-fitting manner in the axial direction and in the radial direction in the direction of the closed side of the receptacle but is freely movable with respect to the connected receptacle and the seal carrier ring or stationary blade ring having this receptacle in the radially opposite direction in the direction of the receptacle opening. | 05-01-2014 |
20140321969 | SLIDE RING SEAL - A turbomachine in the form of a stationary gas turbine or an aircraft engine, respectively a housing structure therefor; the housing structure including an outer housing wall ( | 10-30-2014 |
20150016957 | CERAMIC COMPONENT FOR A TURBOMACHINE - A ceramic component for a turbomachine, the ceramic component ( | 01-15-2015 |
20150102565 | Unknown - The present invention relates to a sealing element ( | 04-16-2015 |